CN103553998B - (S) preparation method of-Oxiracetam crystal form III - Google Patents
(S) preparation method of-Oxiracetam crystal form III Download PDFInfo
- Publication number
- CN103553998B CN103553998B CN201310544263.4A CN201310544263A CN103553998B CN 103553998 B CN103553998 B CN 103553998B CN 201310544263 A CN201310544263 A CN 201310544263A CN 103553998 B CN103553998 B CN 103553998B
- Authority
- CN
- China
- Prior art keywords
- oxiracetam
- preparation
- crystal form
- form iii
- crystal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
Abstract
The preparation method of a kind of (S)-oxiracetam new crystal III, is dissolved in sec-butyl alcohol solvent by (S)-oxiracetam with 5mg/mL-50mg/mL, constantly stirs, 40 DEG C ~ 80 DEG C heating for dissolving, filter, form supersaturated solution; The supersaturated solution obtained sealing is placed on crystallisation by cooling in the low temperature environment of-17 DEG C ~-21 DEG C, and obtaining colourless bulk crystals, is (S)-oxiracetam new crystal III.(S)-oxiracetam new crystal III purity that preparation method of the present invention adopts raw material cheap and easy to get, obtained is high, and preparation method's mild condition is easy and simple to handle, introducing impurity is few, favorable reproducibility, and production process is easy to control, security is high, is applicable to suitability for industrialized production.
Description
Technical field
The present invention relates to field of medicaments, specifically relate to a kind of preparation method, relate to the preparation method of levo-oxiracetam crystal form II I specifically.
Background technology
Oxiracetam was synthesized in 1974 than Qie Mu company first by Italian SmithKline, the nootropic agents of new generation of listing in 1987, pyrrolidinone compounds (ring GABOB) derivative, piracetam analogue, Phosphorylcholine and the synthesis of adjacent acyl thanomin can be promoted, promote brain metabolism, have hormesis by hemato encephalic barrier to specificity central nervous pathway, improve intelligence and memory.To cerebro-vascular diseases, brain injury, brain tumor (postoperative), intracranial infection, dementia, brain degenerative disease etc., there is good efficacy.Be applicable to memory that the diseases such as light moderate vascular dementia, senile dementia and cerebral trauma cause and disturbance of intelligence, to remembering, concentrating of especially thinking is better than piracetam, and toxicity is less.Have report display, the levo form of oxiracetam is higher than dextrorotation activity.
Patent CN102050774A reports a kind of process for purification of oxiracetam compound; Patent CN101121688A discloses improving one's methods of a kind of oxiracetam; Patent CN101575309A, CN101367757, CN101575309 individually disclose the synthetic method of (S)-oxiracetam.Patent CN102249975A discloses (S)-Oxiracetam crystal form I and preparation method thereof.Patent CN102351770B discloses a kind of oxiracetam two crystal type.Patent WO2013/020391A1 discloses S-oxiracetam crystal form II and preparation method.
Research staff chances on, and (S)-oxiracetam, except the crystal formation I that announced and crystal form II, also exists another kind of new crystal.
Crystal formation I alleged by the present invention is the crystal formation in Chinese patent CN102249975A disclosed " (S)-Esomeprazole crystal formation I and its production and use ", and alleged crystal form II is crystal formation disclosed in published Chinese patent CN102558013A " (S)-Esomeprazole crystal form II and preparation method thereof ".
For the polymorphic of medicine, different polymorphics can have different characteristics, as chemical stability, fusing point, apparent solubility, dissolution rate and density etc.These character directly can affect process and the production of bulk drug and preparation, and can affect the stability of preparation, solubleness and bioavailability.In the solid preparation that the polymorphic of medicine is made, solubleness directly affects bioavailability, and usually, the medicine that solubleness is large, bioavailability can be higher.Therefore, the polymorphic of medicine all has great importance with the quality of pharmaceutical preparation, security and validity.
Summary of the invention
The invention provides the preparation method of (S)-Oxiracetam crystal form III, found (S)-oxiracetam new crystal as mentioned below, but for convenience's sake, is called " crystal form II I " by integrity property of the present invention.The method is simple, with low cost, and obtained (S)-Oxiracetam crystal form III purity is high, foreign matter content is low.
The object of the invention is to be achieved through the following technical solutions:
(S) preparation method of-Oxiracetam crystal form III, adopts cooling down mode to prepare, obtains by the following method:
(1). (S)-oxiracetam is dissolved in sec-butyl alcohol solvent with 5mg/mL-50mg/mL, constantly stirs, 40 DEG C ~ 80 DEG C heating for dissolving, filter, form supersaturated solution;
(2). supersaturated solution sealing step (1) obtained is placed on crystallisation by cooling in the low temperature environment of-17 DEG C ~-21 DEG C, and obtaining colourless bulk crystals, is (S)-oxiracetam new crystal III.
In above-mentioned steps (2), crystal littlely reached balance constantly about 24 hours-36 greatly, no longer separated out afterwards.The temperature of described heating for dissolving preferably 40 DEG C ~ 50 DEG C.Low temperature environment preferably-18 DEG C ~-20 DEG C.
Described reaction raw materials and reagent are commercially available prod.
In order to improve yield and the purity of crystal form II I further, be preferably as follows (S)-oxiracetam that mode is obtained:
Intermediate II intermediate III
(S)-oxiracetam
First mixed with the ethanol of 5 ~ 20 times of weight by S-4-amino-3-hydroxybutyrate, then add sulfur oxychloride and react 1 ~ 5 hour at 0 ~ 60 DEG C, S-4-amino-3-hydroxybutyrate and sulfur oxychloride mol ratio are 1:1.5 ~ 1.65; Obtain the alcoholic solution containing intermediate compound I, then collect intermediate compound I from containing the alcoholic solution of intermediate compound I.
The intermediate compound I that will obtain from step (1), in the tetrahydrofuran solvent of the 10-15 times of weight of S-4-amino-3-hydroxybutyrate with halogenated acetic acids ester under triethylamine or lutidine alkali exist catalyzed reaction 5 ~ 10 hours, temperature of reaction is 0 ~ 60 DEG C, then collects and obtains intermediate II; The mol ratio of intermediate compound I and halogenated acetic acids ester is: 1: 1 ~ 3, and the mol ratio of intermediate compound I and described alkaline catalysts is: 1: 2 ~ 3.
By the intermediate II that step (2) obtains, in toluene solvant, carry out ring closure reaction under 50 ~ 120 DEG C of conditions, the time is 3 ~ 8 hours, obtains the solution containing intermediate III, then obtains intermediate III from containing collecting the solution of intermediate III.
By the intermediate III that step (3) obtains, at 20 ~ 30 DEG C, react 4 ~ 16 hours with strong aqua, from reaction product, then collect target product (S)-oxiracetam.
Specifically, the preparation method of above-mentioned (S)-oxiracetam new crystal III:
First S-4-amino-3-hydroxybutyrate is mixed with the ethanol of 5 ~ 20 times of weight, then add sulfur oxychloride to react 1 ~ 5 hour at 0 ~ 60 DEG C, S-4-amino-3-hydroxybutyrate and acylating agent or catalyzer (sulfur oxychloride) mol ratio are 1:1.5 ~ 1.65; Obtain the alcoholic solution containing intermediate compound I, then collect intermediate compound I from containing the alcoholic solution of intermediate compound I.
The intermediate compound I that will obtain from step (1), in the tetrahydrofuran solvent of the 10-15 times of weight of S-4-amino-3-hydroxybutyrate with halogenated acetic acids ester under triethylamine or lutidine alkali exist catalyzed reaction 5 ~ 10 hours, temperature of reaction is 0 ~ 60 DEG C, then collects and obtains intermediate II; The mol ratio of intermediate compound I and halogenated acetic acids ester is: 1: 1 ~ 3, and the mol ratio of intermediate compound I and described alkaline catalysts is: 1: 2 ~ 3.
By the intermediate II that step (2) obtains, in toluene solvant, carry out ring closure reaction under 50 ~ 130 DEG C of conditions, the time is 3 ~ 8 hours, obtains the solution containing intermediate III, then obtains intermediate III from containing collecting the solution of intermediate III.
By the intermediate III that step (3) obtains, at 20 ~ 30 DEG C, react 4 ~ 16 hours with strong aqua, from reaction product, then collect target product (S)-oxiracetam.
(the S)-oxiracetam of above-mentioned collection is dissolved in sec-butyl alcohol solvent with 10mg/mL-50mg/mL, constantly stirs, heat 40 DEG C ~ 50 DEG C dissolvings, filter, form supersaturated solution; The sealing of this solution to be placed in-18 DEG C ~-20 DEG C environment crystallisation by cooling 24 ~ 36 hours, and obtaining colourless bulk crystals, is (S)-oxiracetam new crystal III.
Described reaction raw materials and reagent are commercially available prod.
Beneficial effect of the present invention:
(S)-oxiracetam new crystal III that preparation method of the present invention obtains has oxiracetam equally can promote Phosphorylcholine and the synthesis of adjacent acyl thanomin, promote brain metabolism, hormesis is had to specificity central nervous pathway by hemato encephalic barrier, improve intelligence and memory, to the advantage of memory dysfunction successful.The melting point peak temperature of (the S)-oxiracetam new crystal III prepared by the inventive method is 117.3 DEG C, and in water, dissolution rate is fast, and solubleness >=100mg/mL in water, bioavailability is high.(S)-oxiracetam new crystal III purity that preparation method of the present invention adopts raw material cheap and easy to get, obtained is high, and preparation method's mild condition is easy and simple to handle, introducing impurity is few, favorable reproducibility, and production process is easy to control, security is high, is applicable to suitability for industrialized production.
Accompanying drawing explanation
Fig. 1 is the crystalline structure figure of crystal type (S)-Oxiracetam crystal form III;
Fig. 2 is the structure cell accumulation graph of crystal type (S)-Oxiracetam crystal form III;
Fig. 3 is crystal type (S)-Oxiracetam crystal form III monocrystalline simulation X-ray powder diffraction figure;
Fig. 4 is crystal type (S)-Oxiracetam crystal form III Single Crystal X-ray powder diagram;
Fig. 5 is the Single Crystal X-ray powdery diffractometry comparison diagram of crystal type (S)-Oxiracetam crystal form III, (S)-Oxiracetam crystal form II, (S)-Oxiracetam crystal form I.Be respectively from top to bottom: levo-oxiracetam anhydrous crystal forms (crystal form II I), anhydrous crystal forms (crystal formation I) and 0.5 crystal type (crystal form II).
Embodiment
Below by embodiment, the present invention is specifically described; what be necessary to herein means out is that following examples are only used to further illustrate the present invention; can not be interpreted as limiting the scope of the invention, person skilled in art can make some nonessential improvement and adjustment according to the invention described above content to the present invention.
Embodiment 1
A kind of synthetic method of (S)-oxiracetam, it carries out as follows,
(1) preparation of intermediate compound I:
Get raw material S-4-amino-3-hydroxybutyrate 50g, add in a single neck bottle, add ethanol 250ml, stir, ice-water bath cools, slow instillation thionyl chloride 150ml, keep temperature to be no more than 60 DEG C, solid first has a dissolution process, then separates out again, drip solid when making a concentrated effort to finish to dissolve again, finally form a faint yellow clarified liq.Continue stirring 5 hours, some plate is shown in that raw material primitive reaction is complete, stopped reaction, and directly concentrate except desolventizing obtains pale yellow oil, curing at low temperatures obtains intermediate compound I.Detect through nuclear-magnetism, intermediate compound I is: 1H-NMR (300MHz, D2O): δ 2.76-2.67 (ABsystem, m, 2H), 3.31-3.23 (ABsystem, m, 2H), 3.75 (s, 3H), 4.40 (m, 1H), 4.70 (bs, 3H) .13C-NMR (50MHz, D2O): δ 43.7 (C-2), 48.4 (C-4), 57.0 (OCH), 68.9 (C-3), 177.5 (C-I). intermediate compound I is:
r1 is methyl.
(2) preparation of intermediate II
The intermediate compound I that step (1) obtains is dissolved in the tetrahydrofuran solution of 500ml, be cooled to outer temperature 0 DEG C, add triethylamine (3eq), a large amount of solid is had to generate, stir five minutes, start to drip ethyl bromoacetate 90ml (2eq), dropping process has exothermic phenomenon, dropwise rear continuation stirring 2 hours, point plate is shown in that raw material reaction is complete, stopped reaction, filter, filtrate adds EA (ethyl acetate) 500ml, water 300ml, solid dissolves completely, by saturated for water layer solid sodium chloride, for going out organic layer, water layer EA200ml extracting twice, merge organic layer, the hydrochloric acid 200ml of organic layer 2M washes three times, merge hydrochloric acid aqueous phase, organic phase discards, aqueous phase continuation sodium bicarbonate regulates pH to 8, solid sodium chloride is saturated, EA300ml extracts three times, merge organic phase, anhydrous magnesium sulfate drying, concentrate except desolventizing obtains pale yellow oil, curing at low temperatures obtains intermediate II.Detect through nuclear-magnetism, intermediate II: 1H-NMR (300MHz, D2O): δ 1.3 (t, 3H), 2.28-2.53 (m, 2H), 2.58-2.83 (m, 2H) 3.51 (s, 2H), 3.67 (s, 3H), 4.09-4.12 (m, 3H). intermediate II is:
R1 is methyl, and R2 is ethyl.
(3) preparation of intermediate III
Intermediate II 500ml toluene step (2) obtained dissolves, and is warming up to 120 DEG C, refluxes 8 hours, obtain a red tan solution, and some plate is shown in that raw material reaction is complete.Stopped reaction, concentrated removing toluene, adds EA (ethyl acetate) and dissolves, cross and filter salt, activated carbon decolorizing, concentrate and remove yellow oil obtains intermediate III.Detect through nuclear-magnetism, intermediate III is: 1H-NMR (300MHz, CDCl3) δ 1.280 (t, 3H), 2.38 (dd, 1H), 2.69 (dd, 1H), 3.34 (dd, 1H), 3.77 (dd, 1H), 3.93 (d, 1H), 4.18 (d, 1H), 4.19 (q, 2H), 4.30 (bs, 1H), 4.50 (m, 1H). intermediate III:
r2 is ethyl.
(4) preparation of (S)-oxiracetam
The intermediate III that step (3) obtains is added strong aqua 200ml, stirring at room temperature 18 hours, some plate is shown in that raw material reaction is complete, stopped reaction, concentrated removal water and ammonia, obtain yellow oil, add acetone solution oily matter, add a small amount of crystal seed and stir, separate out solid, a small amount of acetone rinsing bottle wall ,-10 DEG C of crystallizations 5 hours, filter and obtain off-white color crude product 36g.Purity 99.3%, isomer proportion 0.2%.By this dissolving crude product in the water of 100ml, heating makes it dissolve, activated carbon decolorizing half an hour, cross and filter gac, crystallisation by cooling, 5 DEG C of placements are spent the night, filter to obtain white solid 32g next day, purity 99.9%, isomer proportion 0.1%, yield is 48.2%, detect through nuclear-magnetism, levo-oxiracetam: 1H-NMR (300MHz, DMS0-d6) δ 2.10 (d, 1H), 2.57 (dd, 1H), 3.69 (d, 1H), 3.88 (d, 1H), 4.10 (d, 1H), 4.31 (m, 1H), 5.25 (s, 1H), 7.13 (s, 1H), 7.33 (s, 1H). optical value :-37.3.(S)-oxiracetam is that structural formula is as follows:
Embodiment 2
A kind of synthetic method of (S)-oxiracetam, it carries out as follows,
(1) preparation of intermediate compound I:
Get raw material S-4-amino-3-hydroxybutyrate 1g, add in a single neck bottle, add ethanol 20ml, stir, ice-water bath cools, slow instillation thionyl chloride 30ml, keep temperature to be no more than 60 DEG C, solid first has a dissolution process, then separates out again, drip solid when making a concentrated effort to finish to dissolve again, finally form a faint yellow clarified liq.Continue stirring 5 hours, some plate is shown in that raw material primitive reaction is complete, stopped reaction, and directly concentrate except desolventizing obtains pale yellow oil, curing at low temperatures obtains intermediate compound I.Detect through nuclear-magnetism, intermediate compound I is: 1H-NMR (300MHz, D2O): δ 2.76-2.67 (ABsystem, m, 2H), 3.31-3.23 (ABsystem, m, 2H), 3.75 (s, 3H), 4.40 (m, 1H), 4.70 (bs, 3H) .13C-NMR (50MHz, D2O): δ 43.7 (C-2), 48.4 (C-4), 57.0 (OCH), 68.9 (C-3), 177.5 (C-I). intermediate compound I is:
r1 is methyl.
(2) preparation of intermediate II
The intermediate compound I that step (1) obtains is dissolved in the tetrahydrofuran solution of 100ml, be cooled to outer temperature 0 DEG C, add lutidine (1eq), a large amount of solid is had to generate, stir five minutes, start to drip ethyl bromoacetate (2eq), dropping process has exothermic phenomenon, dropwise rear continuation stirring 2 hours, point plate is shown in that raw material reaction is complete, stopped reaction, filter, filtrate adds EA (ethyl acetate) 100ml, water 60ml, solid dissolves completely, by saturated for water layer solid sodium chloride, separate organic layer, water layer EA60ml extracting twice, merge organic layer, the hydrochloric acid 60ml of organic layer 2M washes three times, merge hydrochloric acid aqueous phase, organic phase discards, aqueous phase continuation sodium bicarbonate regulates pH to 8, solid sodium chloride is saturated, EA60ml extracts three times, merge organic phase, anhydrous magnesium sulfate drying, concentrate except desolventizing obtains pale yellow oil, curing at low temperatures obtains intermediate II.Detect through nuclear-magnetism, intermediate II: 1H-NMR (300MHz, D2O): δ 1.3 (t, 3H), 2.28-2.53 (m, 2H), 2.58-2.83 (m, 2H) 3.51 (s, 2H), 3.67 (s, 3H), 4.09-4.12 (m, 3H). intermediate II is:
R1 is methyl, and R2 is ethyl.
(3) preparation of intermediate III
Intermediate II 100ml toluene step (2) obtained dissolves, and is warming up to 120 DEG C, refluxes 8 hours, obtain a red tan solution, and some plate is shown in that raw material reaction is complete.Stopped reaction, concentrated removing toluene, adds EA (ethyl acetate) and dissolves, cross and filter salt, activated carbon decolorizing, concentrate and remove yellow oil obtains intermediate III.Detect through nuclear-magnetism, intermediate III is: 1H-NMR (300MHz, CDCl3) δ 1.280 (t, 3H), 2.38 (dd, 1H), 2.69 (dd, 1H), 3.34 (dd, 1H), 3.77 (dd, 1H), 3.93 (d, 1H), 4.18 (d, 1H), 4.19 (q, 2H), 4.30 (bs, 1H), 4.50 (m, 1H). intermediate III:
r2 is ethyl.
(4) preparation of (S)-oxiracetam
The intermediate III that step (3) obtains is added strong aqua 50ml, stirring at room temperature 18 hours, some plate is shown in that raw material reaction is complete, stopped reaction, concentrated removal water and ammonia, obtain yellow oil, add acetone solution oily matter, add a small amount of crystal seed and stir, separate out solid, a small amount of acetone rinsing bottle wall ,-10 DEG C of crystallizations 5 hours, filter and obtain off-white color crude product 36g.Purity 99.3%, isomer proportion 0.2%.By this dissolving crude product in the water of 100ml, heating makes it dissolve, activated carbon decolorizing half an hour, cross and filter gac, crystallisation by cooling, 5 DEG C of placements are spent the night, filter to obtain white solid 32g next day, purity 99.9%, isomer proportion 0.1%, yield is 48.2%, detect through nuclear-magnetism, levo-oxiracetam: 1H-NMR (300MHz, DMS0-d6) δ 2.10 (d, 1H), 2.57 (dd, 1H), 3.69 (d, 1H), 3.88 (d, 1H), 4.10 (d, 1H), 4.31 (m, 1H), 5.25 (s, 1H), 7.13 (s, 1H), 7.33 (s, 1H). optical value :-37.3.(S)-oxiracetam is that structural formula is as follows:
Embodiment 3
Be dissolved in 2mL sec-butyl alcohol solution by 50mg (S)-oxiracetam obtained for embodiment 1,40 ° of C heating, filter, obtain supersaturated solution, the sealing of this solution to be placed under-19 DEG C of environment cooling crystallization 24 hours, obtaining colourless bulk crystals, is crystal form II I.
Embodiment 4
Crystal type (S) obtained by embodiment 3-Oxiracetam crystal form III crystal parameter is measured.
Resolve the single crystal structure of (S)-Oxiracetam crystal form III, its structure cell is rhombic system, and spacer is P4
1,
α=90.00 °, β=90.00 °, γ=90.00 °, unit cell volume
its crystalline structure as shown in Figure 1, pile up as shown in Figure 2 by structure cell.
The crystallographic parameter of crystal type (S)-Oxiracetam crystal form III is as shown in the table:
aR
1＝Σ||F
o|-|F
c||/ΣF
o|.
bwR
2＝[Σ[w(F
o 2-F
c 2)
2]/Σw(F
o 2)
2]
1/2,w＝1/[σ
2(F
o)
2+(aP)
2+bP],whereP＝[(F
o 2)+2F
c 2]/3.
Described crystal type levo-oxiracetam crystal form II I is 10.54 at angle of diffraction 2 θ, 13.70, 14.44, 15.60, 17.12, 18.88, 19.24, 20.66, 20.84, 21.18, 21.82, 22.94, 23.24, 24.88, 27.20, 27.48, 28.24, 30.46, 30.80, 31.52, 32.00, 32.34, 32.90, 33.20, 34.40, 34.62, 37.30, 37.50, 38.28, 38.96, there is diffraction peak at 40.02 degree of places, its monocrystalline simulation X-ray powder diffraction figure as shown in Figure 3, wherein 2 θ are 14.44, 17.12, 18.88, 19.24, 20.66, 20.84, 21.18 ° of places have the strong peak of diffraction peak to occur.Fig. 3 is the powder diagram that above-mentioned crystal type (S)-oxiracetam is simulated from single crystal structural data, monocrystalline simulation is simulated premised on perfect crystallization, and actual central very difficult appearance is definitely perfect, two close peaks may be caused just to merge and to become a peak, and cause peak broadening.The peak of Fig. 4 and Fig. 3 overlaps substantially, and overlap ratio, more than 99%, technically can think that crystal type (the S)-Oxiracetam crystal form III of preparation is pure single crystal form.
Crystal type of the present invention (S)-Oxiracetam crystal form III, its powder X-ray diffraction pattern is expressed with the per-cent I crystal of spacing d, Bragg angle (2 θ) and relative intensity, as follows:
Embodiment 5
Crystal type (S)-Oxiracetam crystal form III, crystal type (S)-Oxiracetam crystal form II, crystal type (S)-Oxiracetam crystal form I are done powder diffraction experiment contrast, as shown in Figure 5.
Embodiment 6
20mg (S)-oxiracetam is dissolved in 2mL sec-butyl alcohol solution, 50 DEG C of heating, filters, supersaturated solution, the sealing of this solution to be placed under-17 DEG C of environment cooling crystallization 3 hours, to obtain colourless bulk crystals, identifying by the method for embodiment 4, is crystal form II I.
Embodiment 7
50mg (S)-oxiracetam is dissolved in 1mL sec-butyl alcohol solution, 45 DEG C of heating, filters, supersaturated solution, the sealing of this solution to be placed under-18 DEG C of environment cooling crystallization 36 hours, to obtain colourless bulk crystals, identifying by the method for embodiment 4, is crystal form II I.
Embodiment 8
30mg (S)-oxiracetam is dissolved in 6mL sec-butyl alcohol solution, 80 DEG C of heating, filters, obtain supersaturated solution, the sealing of this solution is placed on-20 DEG C of environment lower 24 hours cooling crystallizations, obtains colourless bulk crystals, identifying by the method for embodiment 4, is crystal form II I.
Embodiment 9
70mg (S)-oxiracetam is dissolved in 2mL sec-butyl alcohol solution, 60 DEG C of heating, filters, supersaturated solution, the sealing of this solution to be placed under-21 DEG C of environment cooling crystallization 36 hours, to obtain colourless bulk crystals, identifying by the method for embodiment 4, is crystal form II I.
Embodiment 10
Measure on the LC-MS method basis of left oxiracetam in existing biological sample, healthy Beagle dog 6 is selected in experiment, and body weight is 8 ~ 10kg, is divided into two groups, often organizes 3, be used for observing different crystal forms left oxiracetam oral to dog after bioavailability.Study left oxiracetam I crystal formation and the pharmacokinetics of left oxiracetam III crystal formation in dog body, and be reference preparation with oxiracetam, whether the bioavailability evaluating I crystal formation and III crystal formation is equivalent.And by calculating its pharmacokinetic parameter, evaluation of bioequivalence is carried out to it.Result: left oxiracetam I crystal formation and the main pharmacokinetic parameter of left oxiracetam III crystal formation in Beagle dog body as follows: Tmax is respectively (1.561 ± 0.398), (1.498 ± 0.3988), Cmax are respectively (198.076 ± 80.462), (186.205 ± 50.321) mg/ml; T1/2 is respectively (0.915 ± 0.125), (0.909 ± 0.112) h; AUC0-∞ is respectively (456.268 ± 85.567), (436.364 ± 75.204) mg*h/ml.As can be seen here left oxiracetam I crystal formation and left oxiracetam III crystal formation bioavailability completely the same.
Comparative example 1
10mg (S)-oxiracetam is dissolved in 1mL ethanolic soln, 40 DEG C of heating, filter, obtain supersaturated solution, the sealing of this solution to be placed under-19 DEG C of environment cooling crystallization 24 hours, obtain colourless bulk crystals, identify by the method for X powder diffraction, (angle of diffraction 2 θ is 12.011 to be found to be crystal formation I, 15.318, 17.407, 19.633, 21.228, 22.052, 24.577, 25.223, 27.647, 28.161, 29.109, 30.805, 31.276, 31.766, 32.77, 33.477, 35.252, 35.645, 36.236, 37.379, 39.56, 40.489, 41.256, 41.948, 43.443, there is diffraction peak at 44.628 degree of places).
Comparative example 2
10mg (S)-oxiracetam is dissolved in 1mL butanol solution, 50 DEG C of heating, filter, obtain supersaturated solution, the sealing of this solution to be placed under-19 DEG C of environment cooling crystallization 36 hours, obtain colourless bulk crystals, identify by the method for X powder diffraction, (angle of diffraction 2 θ is 12.011 to be found to be crystal formation I, 15.318, 17.407, 19.633, 21.228, 22.052, 24.577, 25.223, 27.647, 28.161, 29.109, 30.805, 31.276, 31.766, 32.77, 33.477, 35.252, 35.645, 36.236, 37.379, 39.56, 40.489, 41.256, 41.948, 43.443, there is diffraction peak at 44.628 degree of places).
Comparative example 3
10mg (S)-oxiracetam is dissolved in 1mL pyridine solution, 50 DEG C of heating, filters, obtain supersaturated solution, the sealing of this solution to be placed under-17 DEG C of environment cooling crystallization 36 hours, not to have crystal to separate out.
Comparative example 4
10mg (S)-oxiracetam is dissolved in 1mLTHF solution, 50 DEG C of heating, filter, obtain supersaturated solution, the sealing of this solution to be placed under-17 DEG C of environment cooling crystallization 36 hours, obtain colourless bulk crystals, identify by the method for X powder diffraction, being found to be crystal form II (is 10.669 at angle of diffraction 2 θ, 13.25, 13.847, 14.198, 16.729, 17.934, 18.746, 18.816, 20.273, 20.413, 21.431, 21.617, 21.663, 23.38, 24.324, 24.415, 26.069, 26.107, 27.901, 28.621, 28.925, 29.449, 29.484, 31.702, 36.516, 37.685, there is diffraction peak at 39.721 degree of places).
Claims (6)
1. the preparation method of (S)-Oxiracetam crystal form III, is characterized in that, adopts cooling down mode to prepare, specifically adopts following steps:
1) (S)-oxiracetam is dissolved in sec-butyl alcohol solvent, stirs, heating for dissolving, filter, form supersaturated solution;
2) supersaturated solution sealing step (1) obtained is placed on crystallisation by cooling in low temperature environment, and obtaining colourless bulk crystals, is (S)-Oxiracetam crystal form III; Described low temperature environment is-17 DEG C ~-21 DEG C;
Described (S)-Oxiracetam crystal form III is that 10.54,13.70,14.44,15.60,17.12,18.88,19.24,20.66,20.84,21.18,21.82,22.94,23.24,24.88,27.20,27.48,28.24,30.46,30.80,31.52,32.00,32.34,32.90,33.20,34.40,34.62,37.30,37.50,38.28,38.96,40.02 places have diffraction peak at angle of diffraction 2 θ.
2. the preparation method of (S)-Oxiracetam crystal form III as claimed in claim 1, is characterized in that: the temperature of described heating for dissolving is 40 DEG C ~ 80 DEG C.
3. the preparation method of (S)-Oxiracetam crystal form III as claimed in claim 2, is characterized in that: the temperature of described heating for dissolving is 40 DEG C ~ 50 DEG C.
4. the preparation method of (S)-Oxiracetam crystal form III as claimed in claim 3, is characterized in that: described low temperature environment is-18 DEG C ~-20 DEG C.
5. the preparation method of (S)-Oxiracetam crystal form III as described in claim 1 or 4, is characterized by: the soluble end of described (S)-Oxiracetam crystal form III in sec-butyl alcohol is 5mg/mL-50mg/mL.
6. the preparation method of (S)-Oxiracetam crystal form III as claimed in claim 5, is characterized by: the soluble end of described (S)-Oxiracetam crystal form III in sec-butyl alcohol is 10mg/mL-50mg/mL.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310544263.4A CN103553998B (en) | 2013-11-06 | 2013-11-06 | (S) preparation method of-Oxiracetam crystal form III |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310544263.4A CN103553998B (en) | 2013-11-06 | 2013-11-06 | (S) preparation method of-Oxiracetam crystal form III |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103553998A CN103553998A (en) | 2014-02-05 |
| CN103553998B true CN103553998B (en) | 2015-11-25 |
Family
ID=50008406
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310544263.4A Active CN103553998B (en) | 2013-11-06 | 2013-11-06 | (S) preparation method of-Oxiracetam crystal form III |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103553998B (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103554000B (en) * | 2013-11-06 | 2015-03-11 | 重庆润泽医药有限公司 | (S)-oxiracetam crystal form III, and preparation method and application thereof |
| CN105330581A (en) * | 2014-08-07 | 2016-02-17 | 重庆东泽医药科技发展有限公司 | Preparation method for (S)-oxiracetam |
| CN105330582B (en) * | 2014-08-07 | 2018-08-07 | 重庆润泽医药有限公司 | (R) preparation method of-Esomeprazole |
| CN105439936A (en) * | 2014-08-07 | 2016-03-30 | 重庆东泽医药科技发展有限公司 | Oxiracetam preparation method |
| KR20190051059A (en) | 2016-10-24 | 2019-05-14 | 충칭 룬즈 파마슈티컬 컴퍼니 리미티드. | Crystalline Form II of Dextral Oxiracetam, Method for its Preparation and Use Thereof |
| EP3530272A4 (en) | 2016-10-24 | 2020-03-25 | Chongqing Runze Pharmaceutical Company Limited | Novel crystalline form of dextral oxiracetam, preparation method therefor and use thereof |
| JP2019531323A (en) | 2016-10-24 | 2019-10-31 | チョンキン ランゼ ファーマスーティカル カンパニー リミテッド | (R) -4-Hydroxy-2-oxo-1-pyrrolidineacetamide crystal form, preparation method, use |
| CN108299267A (en) * | 2017-01-12 | 2018-07-20 | 重庆润泽医药有限公司 | (R) crystal form and its preparation method and application of -4- hydroxyls -2- oxygen -1- pyrrolidine acetamides |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993006826A1 (en) * | 1991-10-08 | 1993-04-15 | Smithkline Beecham Farmaceutici S.P.A. | Composition comprising s-oxiracetame for use as nootropic |
| US20040204476A1 (en) * | 2001-08-10 | 2004-10-14 | Celal Ates | Oxopyrrolidine compounds, preparations of said compounds and their use in the manufacturing of levetiracetam and analogues |
| CN101367757A (en) * | 2008-10-13 | 2009-02-18 | 重庆润泽医疗器械有限公司 | Preparation method for (S)-4-hydroxyl-2-oxo-1-pyrrolidine ethanamide |
| CN101575309A (en) * | 2009-04-28 | 2009-11-11 | 中国医药集团总公司四川抗菌素工业研究所 | Method for synthesizing (S)-oxiracetam |
| CN101885697A (en) * | 2009-05-15 | 2010-11-17 | 天津药物研究院 | Preparation method of Oxiracetam, product of Oxiracetam and use of product |
| CN102531989A (en) * | 2011-08-11 | 2012-07-04 | 重庆润泽医疗器械有限公司 | Purification method for (S)-oxiracetam |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6228964A (en) * | 1985-07-30 | 1987-02-06 | Matsushita Electric Ind Co Ltd | Recording disk reproducing device |
| JPH06228964A (en) * | 1993-01-28 | 1994-08-16 | ▲緑▼邦實業有限公司 | Stabilizing tree-planting execution method of base rock slope |
-
2013
- 2013-11-06 CN CN201310544263.4A patent/CN103553998B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993006826A1 (en) * | 1991-10-08 | 1993-04-15 | Smithkline Beecham Farmaceutici S.P.A. | Composition comprising s-oxiracetame for use as nootropic |
| US20040204476A1 (en) * | 2001-08-10 | 2004-10-14 | Celal Ates | Oxopyrrolidine compounds, preparations of said compounds and their use in the manufacturing of levetiracetam and analogues |
| CN101367757A (en) * | 2008-10-13 | 2009-02-18 | 重庆润泽医疗器械有限公司 | Preparation method for (S)-4-hydroxyl-2-oxo-1-pyrrolidine ethanamide |
| CN101575309A (en) * | 2009-04-28 | 2009-11-11 | 中国医药集团总公司四川抗菌素工业研究所 | Method for synthesizing (S)-oxiracetam |
| CN101885697A (en) * | 2009-05-15 | 2010-11-17 | 天津药物研究院 | Preparation method of Oxiracetam, product of Oxiracetam and use of product |
| CN102531989A (en) * | 2011-08-11 | 2012-07-04 | 重庆润泽医疗器械有限公司 | Purification method for (S)-oxiracetam |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103553998A (en) | 2014-02-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103553998B (en) | (S) preparation method of-Oxiracetam crystal form III | |
| CN103553999B (en) | Preparation method of (S)-oxiracetam crystal form III | |
| CN103553997B (en) | The preparation method of a kind of (S)-Oxiracetam crystal form III | |
| CN103930419B (en) | The brilliant type of Azilsartan and its preparation method | |
| CN106146379B (en) | A kind of synthetic method of Oxiracetam | |
| WO2006034451A2 (en) | Crystalline clopidogrel hydrobromide and processes for preparation thereof | |
| CN105330582B (en) | (R) preparation method of-Esomeprazole | |
| US20120022047A1 (en) | Process for the purification of eslicarbazepine acetate | |
| CN102702008A (en) | Agomelatine sulfuric acid composition and preparation method thereof | |
| CN101967118B (en) | Preparation method of alvimopan | |
| CN102702041A (en) | Agomelatine benzenesulfonic acid compound and preparation method thereof | |
| CN102947312A (en) | Process for producing pyripyropene derivatives | |
| CN103554000B (en) | (S)-oxiracetam crystal form III, and preparation method and application thereof | |
| CN107814802A (en) | A kind of new method for preparing citric acid tropsch imatinib medicinal crystal-form | |
| US20120101273A1 (en) | Novel crystal forms of adefovir dipivoxil and processes for preparing the same | |
| CN102838579A (en) | Method for preparing 1,3,6,7-tetrahydroxy xanthone | |
| CN106866625B (en) | Preparation method of ketanserin | |
| CN1915998B (en) | Crystalline beta-lactam intermediate | |
| ITMI20011727A1 (en) | LERCANIDIPINE HYDROCHLORIDE SOLVATES AND NEW CRYSTALLINE FORMS OF LERCANIDIPINE HYDROCHLORIDE OBTAINED FROM THEM | |
| CN101987863B (en) | Oleanolic acid piperazine salt and preparation method thereof | |
| CN108069896A (en) | A kind of preparation method of Etoricoxib crystal form | |
| EP2128166A1 (en) | Polymorphic forms of Ibandronate sodium and processes for preparation thereof | |
| CN107021896A (en) | A kind of levo-oxiracetam crystal formation II preparation method | |
| CN107021900A (en) | A kind of (S)-Oxiracetam crystal form II preparation method | |
| CN107021899A (en) | A kind of method for preparing levo-oxiracetam crystal formation II |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20151021 Address after: 325000 Zhejiang city of Wenzhou province Longwan high tech Industrial Park, Aojiang Road No. 81 building two floor B Applicant after: WENZHOU ZHICHUANG TECHNOLOGY CO., LTD. Address before: 400042 Chongqing city Yubei District Qinye Road No. 9 Applicant before: Chongqing Runze Pharmaceutical Co., Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190426 Address after: No. 9, Yubei District industry road, Chongqing, Chongqing Patentee after: Chongqing Runze Pharmaceutical Co., Ltd. Address before: 325000 two, B building, 81 South Road, Longwan high tech Industrial Park, Wenzhou, Zhejiang. Patentee before: WENZHOU ZHICHUANG TECHNOLOGY CO., LTD. |